140 related articles for article (PubMed ID: 19298411)
1. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy.
Shah SR; Freedland SJ; Aronson WJ; Kane CJ; Presti JC; Amling CL; Terris MK
BJU Int; 2009 May; 103(9):1168-72. PubMed ID: 19298411
[TBL] [Abstract][Full Text] [Related]
2. Agent Orange and long-term outcomes after radical prostatectomy.
Ovadia AE; Terris MK; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ; Abern MR
Urol Oncol; 2015 Jul; 33(7):329.e1-6. PubMed ID: 25998746
[TBL] [Abstract][Full Text] [Related]
3. High level of dioxin-TEQ in tissue is associated with Agent Orange exposure but not with biochemical recurrence after radical prostatectomy.
Li Q; Lan L; Klaassen Z; Shah SR; Moses KA; Terris MK
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):376-81. PubMed ID: 24018710
[TBL] [Abstract][Full Text] [Related]
4. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.
Chamie K; DeVere White RW; Lee D; Ok JH; Ellison LM
Cancer; 2008 Nov; 113(9):2464-70. PubMed ID: 18666213
[TBL] [Abstract][Full Text] [Related]
5. Agent Orange exposure, Vietnam war veterans, and the risk of prostate cancer.
Schecter A; Needham L; Pavuk M; Michalek J; Colacino J; Ryan J; Päpke O; Birnbaum L
Cancer; 2009 Jul; 115(14):3369-71. PubMed ID: 19415730
[No Abstract] [Full Text] [Related]
6. Association between Agent Orange and prostate cancer: a pilot case-control study.
Giri VN; Cassidy AE; Beebe-Dimmer J; Ellis L; Smith DC; Bock CH; Cooney KA
Urology; 2004 Apr; 63(4):757-60; discussion 760-1. PubMed ID: 15072895
[TBL] [Abstract][Full Text] [Related]
7. Challenges in investigating the association between Agent Orange and cancer: site-specific cancer risk and accuracy of exposure assessment.
Sinks TH
Cancer; 2014 Dec; 120(23):3595-7. PubMed ID: 25103199
[No Abstract] [Full Text] [Related]
8. Agent Orange as a risk factor for high-grade prostate cancer.
Ansbaugh N; Shannon J; Mori M; Farris PE; Garzotto M
Cancer; 2013 Jul; 119(13):2399-404. PubMed ID: 23670242
[TBL] [Abstract][Full Text] [Related]
9. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
Cancer; 2007 Nov; 110(10):2202-9. PubMed ID: 17876838
[TBL] [Abstract][Full Text] [Related]
10. Does paternal exposure to Agent Orange cause birth defects?
Fraser FC
Am J Med Genet A; 2009 May; 149A(5):835-6. PubMed ID: 19334082
[No Abstract] [Full Text] [Related]
11. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
12. Agent Orange exposure and cancer incidence in Korean Vietnam veterans: a prospective cohort study.
Yi SW; Ohrr H
Cancer; 2014 Dec; 120(23):3699-706. PubMed ID: 25103108
[TBL] [Abstract][Full Text] [Related]
13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
14. Agent Orange in Vietnam. 1995.
Dwyer JH; Flesch-Janys D
Am J Public Health; 2014 Oct; 104(10):1857-60. PubMed ID: 25208001
[No Abstract] [Full Text] [Related]
15. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
16. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
[TBL] [Abstract][Full Text] [Related]
17. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
[TBL] [Abstract][Full Text] [Related]
18. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
[TBL] [Abstract][Full Text] [Related]
19. The relationship between Agent Orange and prostate specific antigen: a comparison of a hotspot and a non-sprayed area in Vietnam.
Sun X; Kido T; Okamoto R; Manh HD; Hoang NV; Nakano M; Koh E; Maruzeni S; Nishijo M; Nakagawa H; Suzuki H; Honma S; Nhu DD; Hung NN; Son le K
Environ Health Prev Med; 2013 Sep; 18(5):356-60. PubMed ID: 23526145
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
